Rosacea Global Market Report 2024

The global rosacea market has grown rapidly in recent years. It will grow from $1.78 billion in 2023 to $1.95 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to growing awareness of rosacea, increasing access to healthcare, rising disposable incomes, government support for rosacea research and treatment,.

The global rosacea market is expected to see strong growth in the next few years. It will grow to $2.76 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to biologic therapies, demand for personalized medicine, aging population, increasing prevalence of comorbidities. Major trends in the forecast period include minimally invasive and non-invasive treatments for rosacea, digital health technologies, rosacea-specific cosmetics, non-invasive therapies.

The increasing prevalence of skin diseases is poised to drive the expansion of the rosacea market in the foreseeable future. Skin diseases encompass a spectrum of medical conditions that affect the skin's appearance, structure, and function, which can involve various skin components. Among these conditions, rosacea, characterized by inflammation and skin problems, may result from different factors, including fungal infections like Candida overgrowth. Furthermore, individuals with rosacea are statistically more prone to developing skin cancers, including hepatic cancer, non-melanoma skin cancer, and breast cancer. For instance, recent data from the American Academy of Dermatology Association, published in April 2022, indicated that approximately 9,500 people in the US receive a skin cancer diagnosis daily. Moreover, according to the Centers for Disease Control and Prevention (CDC), reported in March 2023, the total number of deaths due to fungal infections increased from 5,922 in 2020 to 7,199 in 2021. Hence, the rising prevalence of skin diseases is a driving force behind the growth of the rosacea market.

The growing adoption of telehealth is poised to drive the expansion of the rosacea market in the foreseeable future. Telehealth, which involves the use of digital technologies and communication tools for remote healthcare services, consultations, monitoring, and patient education, has become increasingly prevalent. It empowers patients to access medical care and professional guidance from healthcare providers without the necessity of in-person visits. The growing embrace of telehealth plays a pivotal role in enhancing the management of rosacea. It not only improves healthcare access but also facilitates early intervention, patient education, and treatment adherence. For instance, as of August 2022, data from the Australian Digital Health Agency revealed that over 118.2 million telehealth services were provided to 18 million patients, with more than 95,000 healthcare practitioners utilizing telehealth services during this period. Hence, the escalating adoption of telehealth is a key driver of growth in the rosacea market.

The one of the primary challenges that may hinder the growth of the rosacea market is the persistently low diagnosis rate despite the high prevalence of this condition. The limited diagnosis rate is a significant constraint in the rosacea industry, as it restricts the number of individuals seeking treatment, potentially leading to delayed diagnosis and intervention. The current low diagnosis rate is largely attributed to the lack of awareness and education about rosacea among both healthcare providers and the general population. For example, research from the American Academy of Dermatology reveals that rosacea is significantly underdiagnosed, with prevalence rates ranging from 0.09% to 22.41% among various study groups. Hence, the challenge of low diagnosis rates despite the condition's high prevalence continues to impede the growth of the rosacea market.

The prominent companies in the rosacea market are dedicated to pioneering new products and solutions to maintain their presence in the industry. For example, in June 2022, Galderma S.A., a pharmaceutical company based in Switzerland, introduced EPSOLAY cream, a groundbreaking topical treatment. This cream is the first of its kind to utilize microencapsulated benzoyl peroxide (E-BPO), proven through scientific research to alleviate rosacea-related bumps and blemishes. EPSOLAY Cream leverages Sol-Gel Technology's proprietary patented approach, encapsulating benzoyl peroxide within silica-based microcapsules to establish a protective barrier between the medication and the skin's surface. This innovative method helps reduce the potential irritation and dryness typically associated with traditional benzoyl peroxide treatments.

In March 2022, Novan Inc., a specialty dermatology company based in the United States, completed its acquisition of EPI Health LLC for $27.5 million. This strategic acquisition is expected to empower Novan Inc. in establishing a fully integrated specialty dermatology company. It aims to bolster its presence in the specialty dermatology market and further enrich its product portfolio, particularly in the field of dermatological treatments. EPI Health LLC, a US-based pharmaceutical company, specializes in providing medications for conditions like rosacea, acne, and psoriasis.

Major players in the rosacea market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline PLC, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Galderma S.A., Dr. Reddy's Laboratories Ltd., Lupin Limited, LEO Pharma A/S, Almirall S.A., Supernus Pharmaceuticals Inc., Taro Pharmaceuticals, Mayne Pharma, Aclaris Therapeutics Inc., Sol-Gel Technologies Ltd., Nestle Skin Health S.A., Foamix Pharmaceuticals.

North America was the largest region in the rosacea market in 2023. Asia-Pacific is expected to the fastest-growing region in the forecast period. The regions covered in rosacea report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the rosacea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of rosacea include erythematotelangiectatic rosacea, papulopustular rosacea, ocular rosacea, and phymatous rosacea. Erythematotelangiectatic rosacea is characterized as a chronic inflammatory skin condition primarily affecting the face, and its treatment often involves a combination of topical medications. Various classes of drugs, including antibiotics, alpha-agonists, retinoids, corticosteroids, immunosuppressants, and others, can be administered via various routes, such as topical and oral applications. These treatments serve various end-users, including hospitals, clinics, retail pharmacies, and online pharmacies.

This report provides rosacea market statistics, including rosacea industry global market size, regional shares, competitors with a rosacea market share, detailed rosacea market segments, market trends and opportunities and any further data you may need to thrive in the rosacea industry. This rosacea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rosacea market consists of sales of metronidazole, azelaic acid, brimonidine, oxymetazoline and tretinoin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.